TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 32514886

Group type: EXPERIMENTAL
Intervention: 5-ALA (200 mg/kg intraperitoneal)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: SWIG (5 mg/kg intravenous)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 5-ALA (20 mg/kg oral)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: SWIG (2.5 mg/kg intravenous)
Number of subjects: 20

Group type: COMPARATOR
Intervention: SWIG and 5-ALA
Number of subjects: 20
Study: 32514905

Group type: EXPERIMENTAL
Intervention: Hydrocephalus after ICH
Number of subjects: 1342

Group type: EXPERIMENTAL
Intervention: Hydrocephalus (≤ 3 days)
Number of subjects: 1342

Group type: EXPERIMENTAL
Intervention: Hydrocephalus (4-13 days)
Number of subjects: 1342

Group type: EXPERIMENTAL
Intervention: Hydrocephalus (≥ 14 days)
Number of subjects: 1342

Group type: EXPERIMENTAL
Intervention: All-cause mortality in ICH patients with hydrocephalus
Number of subjects: 1342

Group type: EXPERIMENTAL
Intervention: Favorable outcome in patients with hydrocephalus
Number of subjects: 1342

Group type: EXPERIMENTAL
Intervention: Cause of death in patients with hydrocephalus
Number of subjects: 1342
Study: 32514990

Group type: EXPERIMENTAL
Intervention: CBW/CBW
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: OW/CBW
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: CBW
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: OW
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: CBW/OW
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: OW/OW
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: All interventions
Number of subjects: 12
Study: 32515118

Group type: EXPERIMENTAL
Intervention: Mepolizumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 32515286

Group type: EXPERIMENTAL
Intervention: Pharmacogenomics service led by pharmacists
Number of subjects: 0
Study: 32515349

Group type: EXPERIMENTAL
Intervention: 'agonist-only' Activin A muteins that activate ACVR1B but cannot form the non-signaling complex (NSC) with ACVR1
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (wild-type ACVR1)
Number of subjects: 0
Study: 32515514

Group type: EXPERIMENTAL
Intervention: Dysphagia screening
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Dysarthria screening
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Aphasia screening
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Multivariate binary logistic regression for dysphagia
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Multivariate binary logistic regression for dysarthria
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Multivariate binary logistic regression for aphasia
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Age-adjusted risk for aphasia
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Aphasia association with stroke etiology
Number of subjects: 151
Study: 32515679

Group type: EXPERIMENTAL
Intervention: HER2-targeted PET tracer zirconium 89
Number of subjects: 0
Study: 32515748

Group type: EXPERIMENTAL
Intervention: GUM intervention (integrated physical activity and psychosocial program)
Number of subjects: 101
Study: 32516090

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 32516091

Group type: EXPERIMENTAL
Intervention: Neoadjuvant Cisplatin
Number of subjects: 0
Study: 32516228

Group type: EXPERIMENTAL
Intervention: Pre-operative presepsin measurement
Number of subjects: 222

Group type: COMPARATOR
Intervention: Basic risk model (revised cardiac risk index, high-sensitive cardiac troponin T, N-terminal fragment of pro-brain natriuretic peptide)
Number of subjects: 222

Group type: EXPERIMENTAL
Intervention: Basic risk model + presepsin
Number of subjects: 222
Study: 32516377

Group type: EXPERIMENTAL
Intervention: Pembrolizumab (200 mg, 3 courses)
Number of subjects: 112
Study: 32516414

Group type: EXPERIMENTAL
Intervention: ABVD followed by BV consolidation
Number of subjects: 41
Study: 32516641

Group type: EXPERIMENTAL
Intervention: Subglottic secretion (SS) cultures
Number of subjects: 109
Study: 32516757

Group type: EXPERIMENTAL
Intervention: Upper-limb exoskeleton training for four weeks
Number of subjects: 6
Study: 32517405

Group type: EXPERIMENTAL
Intervention: Erector spinae plane (ESP) block with 20 mL of 0.5% plain bupivacaine
Number of subjects: 18
Study: 32517690

Group type: EXPERIMENTAL
Intervention: Glucocorticoids and hormone replacement
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: FDS (sensitive radiotracer for bacterial infections)
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: FDG PET
Number of subjects: 1
Study: 32517727

Group type: EXPERIMENTAL
Intervention: LIVE intervention with a municipal coordinator facilitating Learning, Innovation, Volunteering, and Empowerment (LIVE) over a 6-month period.
Number of subjects: 315

Group type: COMPARATOR
Intervention: Control group (dyads waiting for the intervention).
Number of subjects: 315
Study: 32517834

Group type: EXPERIMENTAL
Intervention: DietCam
Number of subjects: 30
Study: 32518208

Group type: EXPERIMENTAL
Intervention: hs-cTnT >50 ng/L
Number of subjects: 1642

Group type: EXPERIMENTAL
Intervention: HEART score ≥7
Number of subjects: 1642

Group type: EXPERIMENTAL
Intervention: Combination of hs-cTnT >50 ng/L and a second independent predictor
Number of subjects: 1642
Study: 32518419

Group type: EXPERIMENTAL
Intervention: Ruxolitinib (Rux) - Janus Kinase 1/2 inhibitor, administered with efficacy/toxicity guided step up dosing up to 14 days
Number of subjects: 105
Study: 32518518

Group type: EXPERIMENTAL
Intervention: Nurse-led, person-centred, health-promoting follow-up programme (includes two telephone calls and three visits to a vascular nurse in the first year after surgical treatment)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard care (visit to a vascular surgeon 4-8 weeks after surgery and a visit to the outpatient clinic 1 year after surgical treatment)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nurse-led, person-centred, health-promoting follow-up programme
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 0
Study: 32518597

Group type: EXPERIMENTAL
Intervention: Steroidal aromatase inhibitors
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nonsteroidal aromatase inhibitors
Number of subjects: 0
Study: 32518655

Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIT) (85-95% of peak effort)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Moderate Intensity Continuous Training (MICT)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIT)
Number of subjects: 28
Study: 32518670

Group type: EXPERIMENTAL
Intervention: Usual care plus a six-week mindfulness intervention
Number of subjects: 11
Study: 32518674

Group type: EXPERIMENTAL
Intervention: Movement pattern training (MoveTrain)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Standard strengthening and flexibility
Number of subjects: 46
Study: 32518833

Group type: EXPERIMENTAL
Intervention: Regular cohort (three initial monthly IVT-AFL injections and ≥6 injections)
Number of subjects: 593

Group type: EXPERIMENTAL
Intervention: Irregular cohort with three initial monthly injections
Number of subjects: 593

Group type: COMPARATOR
Intervention: Irregular cohort without three initial monthly injections
Number of subjects: 593

Group type: EXPERIMENTAL
Intervention: Overall cohort (all patients)
Number of subjects: 593

Group type: COMPARATOR
Intervention: Regular cohort vs irregular cohort without three initial monthly injections
Number of subjects: 593

Group type: COMPARATOR
Intervention: Irregular cohort with three initial monthly injections vs irregular cohort without three initial monthly injections
Number of subjects: 593
Study: 32518861

Group type: EXPERIMENTAL
Intervention: Tolvaptan modified-release (MR) 120 mg
Number of subjects: 24

Group type: COMPARATOR
Intervention: Tolvaptan immediate-release (IR) 90+30 mg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Tolvaptan MR (various doses 20 to 120 mg)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Tolvaptan MR and IR
Number of subjects: 24
Study: 32518862

Group type: EXPERIMENTAL
Intervention: Tolvaptan MR 50 mg once daily
Number of subjects: 177

Group type: EXPERIMENTAL
Intervention: Tolvaptan MR 80 mg once daily
Number of subjects: 177

Group type: EXPERIMENTAL
Intervention: Tolvaptan IR 60/30 mg daily split dose
Number of subjects: 177

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 177
Study: 32518891

Group type: EXPERIMENTAL
Intervention: Seasonal trivalent split, inactivated influenza vaccine (TIV) 0.5 ml (15 µg of hemagglutinin per strain)
Number of subjects: 480

Group type: COMPARATOR
Intervention: Placebo (phosphate-buffered saline)
Number of subjects: 480
Study: 32519336

Group type: EXPERIMENTAL
Intervention: ACO-enrolled children
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-ACO managed care plans (control group)
Number of subjects: 0
Study: 32519518

Group type: EXPERIMENTAL
Intervention: Radiotherapy followed by DICEP regimen (Dexamethasone, ifosfamide, cisplatin, etoposide, and pegaspargase)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Radiotherapy followed by DICEP regimen
Number of subjects: 30
Study: 32519555

Group type: EXPERIMENTAL
Intervention: Heart failure with improved ejection fraction (LVEF ≤40% at baseline and improved to >40% at follow-up)
Number of subjects: 2104

Group type: EXPERIMENTAL
Intervention: Persistent heart failure with reduced ejection fraction (persistent HFrEF, LVEF ≤40% at baseline and follow-up)
Number of subjects: 2104

Group type: EXPERIMENTAL
Intervention: Persistent heart failure with preserved ejection fraction (persistent HFpEF, LVEF >40% at baseline and follow-up)
Number of subjects: 2104

Group type: EXPERIMENTAL
Intervention: Heart failure with declined ejection fraction (LVEF >40% at baseline and declined to ≤40% at follow-up)
Number of subjects: 2104

Group type: EXPERIMENTAL
Intervention: All-cause mortality rates
Number of subjects: 2104
Study: 32519889

Group type: EXPERIMENTAL
Intervention: Transcatheter VSD closure
Number of subjects: 60

Group type: COMPARATOR
Intervention: Conservative management (observation group)
Number of subjects: 60
Study: 32520406

Group type: EXPERIMENTAL
Intervention: Lung ultrasound imaging
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Lung ultrasound predictive model
Number of subjects: 100
Study: 32520876

Group type: EXPERIMENTAL
Intervention: Higher protein diet (PRO, ~30% energy from protein; n = 20)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Higher protein diet plus exercise (PRO + EX; n = 19)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Conventional protein control diet plus exercise (CON + EX, ~18% energy from protein; n = 22)
Number of subjects: 72
Study: 32521310

Group type: EXPERIMENTAL
Intervention: Camidanlumab tesirine at 3-92 μg/kg Q3W (n = 26) or 30 or 37.5 μg/kg QW (n = 9)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Camidanlumab tesirine
Number of subjects: 35
Study: 32521607

Group type: EXPERIMENTAL
Intervention: B cell targeted therapies
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Immune-mediated inflammation targeting (CANTOS study)
Number of subjects: 0
Study: 32522161

Group type: EXPERIMENTAL
Intervention: Uncovered self-expanding metal stent (SEMS)
Number of subjects: 113
Study: 32522280

Group type: EXPERIMENTAL
Intervention: Iodine-to-creatinine ratio (I:Cr) at 25th percentile (59 μg/g)
Number of subjects: 6971

Group type: EXPERIMENTAL
Intervention: Iodine-to-creatinine ratio (I:Cr) at 75th percentile (121 μg/g)
Number of subjects: 6971

Group type: COMPARATOR
Intervention: Urinary iodine concentration (UIC)
Number of subjects: 6971

Group type: COMPARATOR
Intervention: Other birth outcomes (stillbirth, preterm birth, ultrasound growth measures, congenital anomalies)
Number of subjects: 6971
Study: 32522676

Group type: EXPERIMENTAL
Intervention: Enrolled patients in the CURES registry
Number of subjects: 14937
Study: 32522679

Group type: EXPERIMENTAL
Intervention: CD34+/KDR+/CD45- cells
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: CD133+/KDR+/CD45- cells
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: Ejection fraction
Number of subjects: 149
Study: 32522743

Group type: EXPERIMENTAL
Intervention: EPP
Number of subjects: 3

Group type: COMPARATOR
Intervention: NP
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: LPP
Number of subjects: 3
Study: 32522846

Group type: EXPERIMENTAL
Intervention: ACE2 activity enhancement drugs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: RAS blockers (ACE inhibitors and angiotensin II receptor blockers)
Number of subjects: 0
Study: 32523075

Group type: EXPERIMENTAL
Intervention: Advanced post-processing methods for predicting prostate cancer aggressiveness
Number of subjects: 0
Study: 32523090

Group type: EXPERIMENTAL
Intervention: E7449 (600 mg, maximum-tolerated dose)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: E7449 (50-800 mg doses)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: E7449 (800 mg)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: E7449 (600 mg)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: E7449
Number of subjects: 41
Study: 32523632

Group type: EXPERIMENTAL
Intervention: nab-paclitaxel plus gemcitabine (nab-P/Gem)
Number of subjects: 102
Study: 32523649

Group type: EXPERIMENTAL
Intervention: Vemurafenib
Number of subjects: 0
Study: 32523648

Group type: EXPERIMENTAL
Intervention: Metformin alone (Arm A)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Metformin with rapamycin (Arm B)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Both arms (A and B)
Number of subjects: 22
Study: 32523724

Group type: EXPERIMENTAL
Intervention: School Health Education Program in Pakistan (SHEPP)
Number of subjects: 982

Group type: COMPARATOR
Intervention: Routine activity (Control)
Number of subjects: 982
Study: 32523873

Group type: EXPERIMENTAL
Intervention: Blended cognitive behavioral therapy (CBT) combining online intervention and in-person guidance.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Internet-delivered cognitive behavioral therapy (iCBT).
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Traditional guided iCBT (email or telephone guidance).
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified.
Number of subjects: 0
Study: 32523972

Group type: EXPERIMENTAL
Intervention: Bezlotoxumab (10 mg/kg)
Number of subjects: 1554

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1554

Group type: EXPERIMENTAL
Intervention: Bezlotoxumab
Number of subjects: 1554
Study: 32524033

Group type: EXPERIMENTAL
Intervention: Intravitreal aflibercept
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Eyes with highest retinal arteriolar oxygen saturation
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Higher retinal arteriolar oxygen saturation
Number of subjects: 25
Study: 32524053

Group type: EXPERIMENTAL
Intervention: Perampanel monotherapy at 4 mg/d during the 26-week Maintenance Period
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Perampanel monotherapy at 4 or 8 mg/d during the 26-week Maintenance Period
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Perampanel monotherapy at 4 mg/d during Maintenance
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Perampanel monotherapy at 4 or 8 mg/d during Maintenance
Number of subjects: 89
Study: 32524257

Group type: EXPERIMENTAL
Intervention: Enzyme replacement therapy (ERT) with alglucosidase alfa
Number of subjects: 396
Study: 32524297

Group type: EXPERIMENTAL
Intervention: Tafamidis
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 32524319

Group type: EXPERIMENTAL
Intervention: ABBV-176 (2.7-109.35 μg/kg)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: ABBV-176
Number of subjects: 19
Study: 32524356

Group type: EXPERIMENTAL
Intervention: Post-transplantation cyclophosphamide (PT-Cy) combined with cyclosporine as GVHD prophylaxis
Number of subjects: 31
Study: 32524580

Group type: EXPERIMENTAL
Intervention: Interpretation biases
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: RSA suppression
Number of subjects: 105
Study: 32524857

Group type: EXPERIMENTAL
Intervention: Sense of coherence (SOC) measured using the 13-item SOC scale (range 13-91)
Number of subjects: 4028

Group type: EXPERIMENTAL
Intervention: Sense of coherence (SOC)
Number of subjects: 4028
Study: 32524920

Group type: EXPERIMENTAL
Intervention: Antidepressant treatment
Number of subjects: 460

Group type: COMPARATOR
Intervention: Healthy controls (HC)
Number of subjects: 460
Study: 32525018

Group type: EXPERIMENTAL
Intervention: Systematic bedside screening for dysphagia within 3 hours postextubation
Number of subjects: 933

Group type: EXPERIMENTAL
Intervention: Baseline neurologic disease
Number of subjects: 933

Group type: EXPERIMENTAL
Intervention: Emergency admission
Number of subjects: 933

Group type: EXPERIMENTAL
Intervention: Days on mechanical ventilation
Number of subjects: 933

Group type: EXPERIMENTAL
Intervention: Days on renal replacement therapy
Number of subjects: 933

Group type: EXPERIMENTAL
Intervention: Disease severity (APACHE II score within first 24 hours)
Number of subjects: 933

Group type: EXPERIMENTAL
Intervention: Increased BMI
Number of subjects: 933
Study: 32525412

Group type: EXPERIMENTAL
Intervention: Harmony transcatheter pulmonary valve (TPV)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Transcatheter valve-in-valve procedure (Melody TPV)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Computed tomography scans
Number of subjects: 20
Study: 32525844

Group type: EXPERIMENTAL
Intervention: Convalescent plasma transfusion
Number of subjects: 5000
Study: 32525901

Group type: EXPERIMENTAL
Intervention: Pelvic fractures (no specific intervention mentioned)
Number of subjects: 184
Study: 32526052

Group type: EXPERIMENTAL
Intervention: Circulating miRNAs (miR-25-3p, miR-93-5p, miR-182-5p, miR-324-5p, miR-363-3p, and miR-451a)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Discovery cohort of 20 patients (10 polyostotic and 10 monostotic)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Real-time qPCR validation phase
Number of subjects: 82
Study: 32526533

Group type: EXPERIMENTAL
Intervention: Warfarin
Number of subjects: 10005

Group type: EXPERIMENTAL
Intervention: DOACs
Number of subjects: 10005

Group type: COMPARATOR
Intervention: Warfarin or DOACs
Number of subjects: 10005
Study: 32526633

Group type: EXPERIMENTAL
Intervention: Renal Resistive Index (RRI)
Number of subjects: 371

Group type: EXPERIMENTAL
Intervention: Venous Impedance Index (VII)
Number of subjects: 371

Group type: EXPERIMENTAL
Intervention: Overall diagnostic accuracy of RRI and VII
Number of subjects: 371
Study: 32527223

Group type: EXPERIMENTAL
Intervention: Dynamic standing sessions
Number of subjects: 12

Group type: COMPARATOR
Intervention: Static standing sessions
Number of subjects: 12

Group type: COMPARATOR
Intervention: Sitting
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Prolonged 4-h standing
Number of subjects: 12
Study: 32527240

Group type: EXPERIMENTAL
Intervention: CT ASPHINA 409 IOL
Number of subjects: 282
Study: 32527396

Group type: EXPERIMENTAL
Intervention: Renal denervation (RDN)
Number of subjects: 2652
Study: 32527643

Group type: EXPERIMENTAL
Intervention: Autologous anti-EGFR chimeric antigen receptor-modified T (CAR T-EGFR) cells, median dose of CAR T cells: 3.48 × 10^6 cells, administered in one to three cycles within 6 months.
Number of subjects: 16
Study: 32527687

Group type: EXPERIMENTAL
Intervention: Dance practitioner midwife group (DPMG)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Dance practitioner spouse/partner group (DPSG)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 160
Study: 32527719

Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention (ILI)
Number of subjects: 158
Study: 32527868

Group type: EXPERIMENTAL
Intervention: Kawa-COVID-19 cohort
Number of subjects: 16
Study: 32527993

Group type: EXPERIMENTAL
Intervention: Home-based physical activity
Number of subjects: 3096

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 3096
Study: 32528286

Group type: EXPERIMENTAL
Intervention: Olanzapine treatment for 12 weeks
Number of subjects: 33
Study: 32528389

Group type: EXPERIMENTAL
Intervention: Dog-assisted therapy (DAT)
Number of subjects: 33
Study: 32528460

Group type: EXPERIMENTAL
Intervention: CAR T-cell products manufactured using CliniMACS Prodigy system with CD4-CD8 cell selection, lentiviral transduction, and T-cell expansion using IL-7/IL-15
Number of subjects: 28
Study: 32528722

Group type: EXPERIMENTAL
Intervention: Optimized APD (7 × 2 L 2.27% + 5 × 2 L 0.1% over 8 h)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Standard APD (6 × 2 L 1.36% over 9 h)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Optimized APD
Number of subjects: 20

Group type: COMPARATOR
Intervention: Standard APD
Number of subjects: 20
Study: 32528919

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 32529175

Group type: EXPERIMENTAL
Intervention: Doxycycline for 1 year along with chemotherapy
Number of subjects: 25
Study: 32529176

Group type: EXPERIMENTAL
Intervention: Needle-free insulin injector (NFII)
Number of subjects: 427

Group type: COMPARATOR
Intervention: Conventional insulin pen (CIP)
Number of subjects: 427
Study: 32529495

Group type: EXPERIMENTAL
Intervention: Certolizumab pegol (CZP) 400 mg loading dose at weeks 0, 2, and 4, followed by 200 mg every 2 weeks up to week 48
Number of subjects: 736

Group type: EXPERIMENTAL
Intervention: Certolizumab pegol (CZP) treatment
Number of subjects: 736
Study: 32530434

Group type: EXPERIMENTAL
Intervention: Customizable colored LED lighting system
Number of subjects: 35
Study: 32530436

Group type: EXPERIMENTAL
Intervention: Safe City game-based intervention
Number of subjects: 1008

Group type: COMPARATOR
Intervention: Traditional instructional materials (electronic and printed safety information)
Number of subjects: 1008
Study: 32530764

Group type: EXPERIMENTAL
Intervention: Ivosidenib (500 mg once per day)
Number of subjects: 66
Study: 32530768

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 32530906

Group type: EXPERIMENTAL
Intervention: Low-Volume High-Intensity Interval Training (LV-HIIT)
Number of subjects: 42
Study: 32531030

Group type: EXPERIMENTAL
Intervention: AF ablation
Number of subjects: 230
Study: 32531326

Group type: EXPERIMENTAL
Intervention: Second-line treatment with insulin, meglitinides or sulphonylureas
Number of subjects: 0

Group type: COMPARATOR
Intervention: Metformin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Overall population
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Middle-income countries
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fear of hypoglycaemia
Number of subjects: 0
Study: 32531990

Group type: EXPERIMENTAL
Intervention: Conventional disease-modifying anti-rheumatic drug (cDMARD) therapy
Number of subjects: 0